An anti-programmed cell death 1 (PD-1) mAb and anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) mAb are treatments studied in a variety of malignant tumours, including cervical cancer [6, 7]. This evidence concerns the gene PDCD1 and cervical cancer.